Evolus EOLS
NASDAQ EOLS
$8.35 -0.25 (-2.91%)
At close: Aug 20, 2026 · 4:00 PM EDT

Evolus (EOLS) Gains from Investment Securities (2018 - 2026)

Evolus' (EOLS) quarterly Gains from Investment Securities came in at -$14000.0 in Q1 2026, down 100.65% YoY from $2.2 million in Q1 2025, and up 99.69% on a QoQ basis from -$4.5 million in Q4 2025.

Evolus (EOLS) Gains from Investment Securities (2018 - 2026) Analysis & Trends

Evolus (EOLS) has 9 years of Gains from Investment Securities data on file, last reported at -$14000.0 in Q1 2026.

  • Quarterly Gains from Investment Securities fell 100.65% year-over-year to -$14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.5 million (down 210.29% YoY) and the FY2025 annual result came in at -$6.4 million, down 188.92% from the prior year.
  • Gains from Investment Securities climbed to -$14000.0 in Q1 2026, from -$4.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.4 million in Q3 2024 to a low of -$4.5 million in Q4 2025.
  • A 5-year average of $634882.4 and a median of $1.6 million in 2024 frame the typical range for Gains from Investment Securities.
  • Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 278.86% — and 2025, when it slumped 388.24%.
  • Tracing EOLS's Gains from Investment Securities over 5 years: stood at $1.8 million in 2022, then tumbled by 148.37% to -$875000.0 in 2023, then surged by 278.86% to $1.6 million in 2024, then tumbled by 388.24% to -$4.5 million in 2025, then soared by 99.69% to -$14000.0 in 2026.
  • The last three Gains from Investment Securities figures came in at -$14000.0 (Q1 2026), -$4.5 million (Q4 2025), and -$107000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.83 Bn 42.86 Bn -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn -
10 Evolus 552.49 Mn 507.32 Mn 57.18 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 1.25 Mn
Jun 30, 2026 1.25 Mn
Mar 31, 2026 -14,000.00
Mar 31, 2026 -14,000.00
Dec 31, 2025 -4.51 Mn
Dec 31, 2025 -4.51 Mn
Sep 30, 2025 -107,000.00
Sep 30, 2025 -107,000.00
Jun 30, 2025 -3.91 Mn
Jun 30, 2025 -3.91 Mn
Mar 31, 2025 2.15 Mn
Mar 31, 2025 2.15 Mn
Dec 31, 2024 1.57 Mn
Dec 31, 2024 1.57 Mn
Sep 30, 2024 2.43 Mn
Sep 30, 2024 2.43 Mn
Jun 30, 2024 1.61 Mn
Jun 30, 2024 1.61 Mn
Mar 31, 2024 1.58 Mn
Mar 31, 2024 1.58 Mn